| 1 |
NCT03102918 |
Completed
Has Results |
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Self-report Instruments to Measure Cannabis Use
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03102918 |
2015P002013 |
CBD |
February 20, 2016 |
August 30, 2017 |
August 30, 2017 |
April 6, 2017 |
January 25, 2019 |
January 25, 2019 |
- McLean Hospital
Belmont, Massachusetts, United States
|
|
| 2 |
NCT03634189 |
Not yet recruiting |
Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C |
|
|
Interventional
|
Phase 1 |
- Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related serious adverse events and events of interest as assessed by MedDRA v5.1
|
20 |
All |
30 Years to 75 Years (Adult, Older Adult) |
NCT03634189 |
CAPITAL-AC |
CAPITAL-AC |
March 1, 2019 |
September 1, 2019 |
March 1, 2020 |
August 16, 2018 |
November 14, 2018 |
|
|
|
| 3 |
NCT02548559 |
Recruiting |
Sublingual Cannabidiol for Anxiety |
|
|
Interventional
|
Phase 2 |
- Staci Gruber, Ph.D.
- Mclean Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change from Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI)
- Change from Baseline in Anxiety Assessed by the Hamilton Anxiety Scale (HAM-A)
- Change from Baseline in Self-Reported Anxiety Assessed by the State-Trait Anxiety Inventory (STAI)
|
16 |
All |
18 Years and older (Adult, Older Adult) |
NCT02548559 |
2015P000959 |
|
August 14, 2018 |
August 2019 |
August 2019 |
September 14, 2015 |
August 15, 2018 |
|
- McLean Hospital Brain Imaging Center
Belmont, Massachusetts, United States
|
|
| 4 |
NCT03310593 |
Recruiting |
Cannabidiol as an Adjunctive Treatment for Bipolar Depression |
- Bipolar Disorder
- Bipolar Depression
- Bipolar Affective Disorder
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Hospital de Clinicas de Porto Alegre
- Federal University of Rio Grande do Sul
- University of Sao Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline Montgomery-Asberg Depression Rating Scale (MADRS) scores.
- Improvement in clinical global impression.
- Improvement in anxiety symptoms
- (and 11 more...)
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03310593 |
63811317300005327 |
CBDBD |
November 1, 2017 |
October 2019 |
February 2020 |
October 16, 2017 |
December 18, 2018 |
|
- Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande Do Sul, Brazil
|
|
| 5 |
NCT02332655 |
Active, not recruiting |
Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome |
|
|
Interventional
|
Phase 1
Phase 2 |
- Anne Comi, MD
- GW Pharmaceuticals Ltd.
- Faneca 66 Foundation
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in seizure frequency
- Change in average seizure duration by seizure type
- Change in the number of episodes of status epilepticus, defined as convulsive seizure lasting longer than 10 minutes
- (and 2 more...)
|
10 |
All |
1 Month to 45 Years (Child, Adult) |
NCT02332655 |
IRB00029264 |
|
December 2014 |
June 2019 |
June 2019 |
January 7, 2015 |
January 8, 2019 |
|
- Kennedy Krieger Institute
Baltimore, Maryland, United States
|
|
| 6 |
NCT03355300 |
Recruiting |
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures |
- Childhood Absence Epilepsy
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Number of Participants with Change from Baseline in Vital Signs at Visit 8
- Number of Participants with Change from Baseline in Physical Exam at Visit 8
- (and 3 more...)
|
30 |
All |
3 Years to 17 Years (Child) |
NCT03355300 |
INS011-17-113 |
|
February 20, 2018 |
November 2019 |
November 2019 |
November 28, 2017 |
February 5, 2019 |
|
- Nicklaus Children's Hospital
Miami, Florida, United States - Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, United States - Clinical Integrative Research Center of Atlanta
Atlanta, Georgia, United States - (and 6 more...)
|
|
| 7 |
NCT03336242 |
Recruiting |
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures |
- Childhood Absence Epilepsy
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent Change from Baseline in Absence Seizure Counts Assessed by Video-electroencephalogram (EEG) at Visit 5
- Percent Change from Baseline in Time to Absence Seizure During Hyperventilation Testing on Video-EEG at Visit 5
- Percentage of Participants Seizure-Free at Visit 5
- (and 7 more...)
|
30 |
All |
3 Years to 17 Years (Child) |
NCT03336242 |
INS011-17-103 |
|
December 15, 2017 |
February 2019 |
February 2019 |
November 8, 2017 |
February 5, 2019 |
|
- University of California San Francisco/ Benioff Children's Hospital
San Francisco, California, United States - Nicklaus Children's Hospital
Miami, Florida, United States - Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, United States - (and 8 more...)
|
|
| 8 |
NCT03248167 |
Not yet recruiting |
Cannabidiol as a Treatment for AUD Comorbid With PTSD |
- Alcohol Use Disorder
- Post Traumatic Stress Disorder
|
- Drug: Cannabidiol
- Drug: Placebos
|
Interventional
|
Phase 1
Phase 2 |
- New York University School of Medicine
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of drinks per day
- Weekly percentage of heavy drinking days
- Weekly percentage of very heavy drinking days
- (and 8 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03248167 |
17-00949 |
|
November 15, 2018 |
August 31, 2019 |
August 31, 2019 |
August 14, 2017 |
April 6, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 9 |
NCT01596075 |
Unknown † |
Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation |
- Graft Versus Host Disease
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete resolution of acute GVHD
- Percentage of patients developing chronic GVHD
- percentage of patients developing > or = grade 3 toxicity
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT01596075 |
0388-11-RMC |
|
July 2012 |
July 2015 |
|
May 10, 2012 |
September 11, 2012 |
|
- Davidof Cancer Center, Beilinson hospital, Rabin medical center
Petach Tikva, Israel
|
|
| 10 |
NCT03164512 |
Recruiting |
The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol |
- Cannabidiol Pharmacokinetics
|
- Drug: Oral or vaporized cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
|
24 |
All |
18 Years to 45 Years (Adult) |
NCT03164512 |
IRB00128331 |
|
June 1, 2018 |
August 30, 2019 |
August 30, 2019 |
May 23, 2017 |
July 16, 2018 |
|
- Johns Hopkins Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States
|
|
| 11 |
NCT02324673 |
Completed
Has Results |
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol
- Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol
- Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol
- (and 28 more...)
|
61 |
All |
1 Year to 17 Years (Child) |
NCT02324673 |
INS011-14-029 |
|
April 13, 2015 |
May 9, 2016 |
May 9, 2016 |
December 24, 2014 |
June 23, 2017 |
June 23, 2017 |
- University of California San Francisco Medical Center
San Francisco, California, United States - Miami Children's Hospital
Miami, Florida, United States - Child Neurology Center - NW F
Pensacola, Florida, United States - (and 7 more...)
|
|
| 12 |
NCT02660255 |
Available |
Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy |
|
|
Expanded Access
|
|
- Deepak Madhavan MD
- GW Pharmaceuticals Ltd.
- University of Nebraska
|
Other / Industry |
|
|
|
All |
1 Year to 60 Years (Child, Adult) |
NCT02660255 |
719-15-FB |
CBD |
February 2016 |
May 2018 |
May 2018 |
January 21, 2016 |
May 3, 2017 |
|
|
|
| 13 |
NCT01385124 |
Unknown † |
Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation |
- Graft Versus Host Disease
|
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Overall percentage of patients with acute GVHD at day 100 post-transplant
- Percentage of patients with grade III/IV acute GVHD at day 100 post-transplant
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01385124 |
6276 |
|
September 2012 |
December 2015 |
|
June 29, 2011 |
June 19, 2015 |
|
- Davidoff Cancer Center, Beilin hospital, Rabin medical center
Petach Tikva, Israel
|
|
| 14 |
NCT03458416 |
Recruiting |
A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) Associated with Cannabidiol Oral Solution
- Number of Participants with Change from Baseline in Vital Signs
- Number of Participants with Change from Baseline in Physical Exam
- (and 3 more...)
|
66 |
All |
8 Years to 17 Years (Child) |
NCT03458416 |
INS011-17-115 |
|
September 6, 2018 |
May 2020 |
May 2020 |
March 8, 2018 |
February 5, 2019 |
|
- Institute for Research and Innovation | MultiCare Health System
Tacoma, Washington, United States
|
|
| 15 |
NCT03676049 |
Available |
Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use) |
|
|
Expanded Access
- Intermediate-size Population
|
|
- John
- University of Mississippi Medical Center
|
Other |
|
|
|
All |
5 Years to 19 Years (Child, Adult) |
NCT03676049 |
2017-0259 |
|
|
|
|
September 18, 2018 |
September 18, 2018 |
|
- University of Mississippi Medical Center
Jackson, Mississippi, United States
|
|
| 16 |
NCT02286986 |
Active, not recruiting |
Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy |
|
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Seizure Frequency
- Drug Plasma Levels of Cannabidiol
|
25 |
All |
2 Years to 25 Years (Child, Adult) |
NCT02286986 |
IND 70871 |
|
September 2014 |
January 2019 |
April 2019 |
November 10, 2014 |
July 19, 2018 |
|
- University of Utah School of Medicine
Salt Lake City, Utah, United States
|
|
| 17 |
NCT01311778 |
Completed |
Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse |
|
- Drug: Cannabidiol
- Drug: Fentanyl
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To determine the safety of cannabidiol oral administration prior to fentanyl IV administration.
- General cannabidiol pharmacokinetics
- Cortisol levels
- (and 11 more...)
|
18 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01311778 |
R21DA027781 |
|
February 2010 |
October 2011 |
October 2011 |
March 10, 2011 |
March 22, 2013 |
|
- Mount Sinai Medical Center
New York, New York, United States
|
|
| 18 |
NCT01037322 |
Completed |
Cannabidiol for Inflammatory Bowel Disease |
- Crohn's Disease
- Ulcerative Colitis
|
- Drug: cannabidiol
- Drug: placebo in drops
|
Interventional
|
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- reduction of 70 points in CDAI
- change in quality of life during the study
- any adverse events during study period
|
20 |
All |
20 Years to 80 Years (Adult, Older Adult) |
NCT01037322 |
canabidiol1 |
|
January 2010 |
September 2012 |
September 2012 |
December 23, 2009 |
April 16, 2013 |
|
- Sapir Medical center Meir Hospital
Kefar Saba, Israel
|
|
| 19 |
NCT02551731 |
Terminated
Has Results |
Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part A: Percentage of Participants Who Are Considered Complete Responders at Day 14
- Part B: Percentage of Participants Experiencing Adverse Events (AEs), Treatment-Emergent AEs (TEAEs), and Serious Adverse Events (SAEs)
- Part A: Percentage of Participants With Absence of Infantile Spasms at Day 14
- (and 11 more...)
|
9 |
All |
6 Months to 36 Months (Child) |
NCT02551731 |
INS011-15-054 |
|
January 27, 2016 |
September 6, 2016 |
September 6, 2016 |
September 16, 2015 |
September 19, 2018 |
September 19, 2018 |
- Mattel Children's Hospital at UCLA
Los Angeles, California, United States - University of California - San Francisco
San Francisco, California, United States - Miami Children's Hospital
Miami, Florida, United States - Beaumont Health System
Royal Oak, Michigan, United States
|
|
| 20 |
NCT03014440 |
No longer available |
Study of Cannabidiol for Drug-Resistant Epilepsies |
|
|
Expanded Access
|
|
- Eric Marsh, MD
- University of Pittsburgh
- Geisinger Clinic
- Children's Hospital of Philadelphia
|
Other |
|
|
|
All |
1 Year to 20 Years (Child, Adult) |
NCT03014440 |
13-010562 |
|
|
|
|
January 9, 2017 |
April 4, 2017 |
|
|
|
| 21 |
NCT03471559 |
Recruiting |
Cannabidiol - an in Vivo Innovative Drug Delivery Study |
- Pharmacokinetics, Bioavailability
|
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Pharmacokinetic profile of single dose - area under the curve (AUC(0-t)), AUC(0-∞))
- Pharmacokinetic profile of single dose - residual area
- Pharmacokinetic profile of single dose - maximum concentration (Cmax)
- (and 13 more...)
|
24 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03471559 |
CBD-DDS |
|
December 10, 2018 |
May 31, 2019 |
August 31, 2019 |
March 20, 2018 |
December 13, 2018 |
|
- Department I of Pharmacology, University of Cologne
Cologne, Germany
|
|
| 22 |
NCT02318563 |
Withdrawn |
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo Solution
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components
- Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
- Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
- (and 5 more...)
|
0 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02318563 |
INS011-14-025 |
|
December 30, 2017 |
June 17, 2018 |
June 17, 2018 |
December 17, 2014 |
January 4, 2018 |
|
|
|
| 23 |
NCT03252756 |
Not yet recruiting |
Effects of Cannabidiol in Alcohol Use Disorder |
|
- Other: Placebo
- Drug: Phytocannabinoid cannabidiol (CBD)
|
Interventional
|
Phase 1
Phase 2 |
- New York University School of Medicine
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in Time-line Follow-back (TLFB) assessment of alcohol consumption in Serum
- Change in Percent carbohydrate deficient transferrin (CDT) assessment of alcohol consumption in Serum
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03252756 |
17-01001 |
|
April 15, 2019 |
November 2019 |
January 2020 |
August 17, 2017 |
January 25, 2019 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 24 |
NCT02318537 |
Withdrawn |
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo Solution
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percent change from baseline in the frequency of motor seizures involving the trunk or extremities [tonic, atonic, generalized tonic-clonic (GTC), focal seizures with motor components (FSMC)]
- Percent change from baseline in severity of motor seizures involving the trunk or extremities (tonic, clonic, GTC, FSMC)
- Percent change from baseline in frequency of all seizure activity independent of seizure type
- (and 6 more...)
|
0 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02318537 |
INS011-14-024 |
|
December 30, 2017 |
June 30, 2018 |
June 30, 2018 |
December 17, 2014 |
January 4, 2018 |
|
|
|
| 25 |
NCT03787628 |
Not yet recruiting |
Cannabidiol as Adjunctive Treatment for Opioid Use Disorder |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cue-induced opioid craving
- spontaneous opioid craving using the Penn Alcohol-Craving Scale adapted for opioid
- Spielberger State-Trait Anxiety Inventory
- (and 10 more...)
|
60 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03787628 |
18-001748 |
|
March 1, 2019 |
January 31, 2021 |
March 31, 2021 |
December 25, 2018 |
December 25, 2018 |
|
|
|
| 26 |
NCT03549819 |
Not yet recruiting |
Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study |
- Generalized Anxiety Disorder
- Social Anxiety Disorder
- Panic Disorder
- Agoraphobia
|
- Drug: Cannabidiol (CBD) Oil Capsules
- Drug: Sunflower Lecithin Oil in Capsule
|
Interventional
|
Phase 3 |
- McMaster University
- Tilray
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Anxiety Rating Scale (HAM-A)
- Clinical Global Impression - Severity (CGI-S)
- Clinical Global Impression - Improvement (CGI-I)
- (and 25 more...)
|
50 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03549819 |
CBD_ANX |
|
August 2018 |
August 2020 |
October 2020 |
June 8, 2018 |
June 8, 2018 |
|
- MacAnxiety Research Centre
Hamilton, Ontario, Canada
|
|
| 27 |
NCT02844933 |
Recruiting |
Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the total score of the Hyperphagia Questionnaire for Clinical Trial (HQ-CT)
- Change from Baseline in Total Body-Weight
- Responder Rate from Baseline through Study Completion
- (and 4 more...)
|
66 |
All |
8 Years to 17 Years (Child) |
NCT02844933 |
INS011-16-085 |
|
June 6, 2018 |
June 2019 |
June 2019 |
July 26, 2016 |
February 5, 2019 |
|
- Rady Children's, UC San Diego
San Diego, California, United States - Institute for Research and Innovation | MultiCare Health System
Tacoma, Washington, United States
|
|
| 28 |
NCT02556008 |
No longer available |
Cannabidiol for Pediatric Epilepsy (Compassionate Use) |
- Refractory Childhood Epilepsy
|
|
Expanded Access
|
|
- University of California, Los Angeles
|
Other |
|
|
|
All |
1 Year to 17 Years (Child) |
NCT02556008 |
SH001 |
|
|
|
|
September 22, 2015 |
May 3, 2017 |
|
- University of California, Los Angeles
Los Angeles, California, United States
|
|
| 29 |
NCT02559167 |
Recruiting |
Cannabidiol and Cocaine Craving/Dependence |
- Substance Use Disorder
- Cocaine Dependence
- Withdrawal From Addictive Substance; Detoxification
|
|
Interventional
|
Phase 2 |
- Didier Jutras-Aswad
- Centre hospitalier de l'Université de Montréal (CHUM)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Drug-cue induced craving
- Number of days to relapse
- Stress-induced craving
- Cocaine use during the post-detoxification phase
|
110 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02559167 |
14.183 |
CBD |
February 2016 |
September 2019 |
December 2019 |
September 24, 2015 |
January 31, 2019 |
|
- Centre de recherche du Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
|
|
| 30 |
NCT03196934 |
Available |
Expanded Use of Cannabidiol Oral Solution |
|
- Drug: Cannabidiol oral solution
|
Expanded Access
- Intermediate-size Population
|
|
- Steven Phillips
- MultiCare Health System Research Institute
|
Other |
|
|
|
All |
1 Year to 18 Years (Child, Adult) |
NCT03196934 |
MulticareHSRI |
|
|
|
|
June 23, 2017 |
June 23, 2017 |
|
|
|
| 31 |
NCT02818777 |
Recruiting |
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease |
|
- Drug: cannabidiol
- Drug: placebo
|
Interventional
|
Phase 2 |
- University of Colorado, Denver
- Colorado Department of Public Health and Environment
- GW Research Ltd
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of study-related adverse events at each dose level
- Changes in Vital Signs
- Changes in Physical Exam
- (and 21 more...)
|
60 |
All |
45 Years to 78 Years (Adult, Older Adult) |
NCT02818777 |
15-0929 |
|
July 2016 |
December 2018 |
June 2019 |
June 30, 2016 |
April 28, 2017 |
|
- University of Colorado School of Medicine
Aurora, Colorado, United States
|
|
| 32 |
NCT03467620 |
Not yet recruiting |
Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease |
- Crohn Disease
- Inflammatory Bowel Diseases
- Cannabis
|
- Drug: Cannabidiol
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2
Phase 3 |
- University of Illinois at Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- CDAI (Clinical Disease Activity Index) score
- Fecal calprotectin
- Morbidity
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03467620 |
CBD2018 |
|
July 2018 |
July 2019 |
July 2019 |
March 16, 2018 |
March 20, 2018 |
|
|
|
| 33 |
NCT03421496 |
Recruiting |
A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms |
|
- Drug: Cannabidiol Oral Solution
- Drug: Placebo
- Drug: Vigabatrin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Considered Complete Responders
- Percentage of Participants with Resolution of Infantile Spasms
- Percentage of Participants with Resolution of Hypsarrhythmia
- (and 3 more...)
|
190 |
All |
1 Month to 24 Months (Child) |
NCT03421496 |
INS011-16-082 |
|
September 5, 2018 |
December 2019 |
December 2019 |
February 5, 2018 |
February 5, 2019 |
|
- Nicklaus Children's Hospital
Miami, Florida, United States - Beaumont Children's Hospital
Royal Oak, Michigan, United States - Akron Children's Hospital
Akron, Ohio, United States - (and 2 more...)
|
|
| 34 |
NCT01605539 |
Completed
Has Results |
Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans |
|
- Drug: Cannabidiol 400
- Drug: Cannabidiol 800
- Drug: Control
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC)
- Changes in Out-of-Clinic Craving (From Pre-Dose to Approximately 6 Hours Post-Dose for Test Visits I and II; and From Pre-Dose Test Visit I to Pre-Cue Test Visit IV) - Via the Heroin Craving Questionnaire (HCQ)
- Vital Signs - Blood Pressure
- (and 6 more...)
|
10 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT01605539 |
R21 DA027781(2) |
|
May 2012 |
October 2013 |
October 2013 |
May 25, 2012 |
November 28, 2016 |
November 28, 2016 |
- Mount Sinai Medical Center
New York, New York, United States
|
|
| 35 |
NCT02902081 |
Completed |
Cannabidiol and Emotional Stimuli |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Not Applicable |
- University of Chicago
- INSYS Therapeutics Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Responses to Negative Stimuli
- Emotional Recognition
|
38 |
All |
18 Years to 35 Years (Adult) |
NCT02902081 |
IRB13-0215 |
CAS |
February 2013 |
March 2017 |
March 2017 |
September 15, 2016 |
June 1, 2017 |
|
- University of Chicago
Chicago, Illinois, United States
|
|
| 36 |
NCT03518801 |
Not yet recruiting |
Cannabidiol and Prolonged Exposure |
|
- Behavioral: Prolonged Exposure
- Drug: Cannabidiol
- Drug: placebo
|
Interventional
|
Phase 2 |
- VA Office of Research and Development
- University of California, San Diego
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinician-Administered PTSD Scale DSM 5 (CAPS-5)
- PTSD Checklist (PCL-5)
|
136 |
All |
18 Years and older (Adult, Older Adult) |
NCT03518801 |
MHBB-001-17F |
CBD-PE |
February 11, 2019 |
September 30, 2023 |
September 30, 2023 |
May 8, 2018 |
February 6, 2019 |
|
- VA San Diego Healthcare System, San Diego, CA
San Diego, California, United States
|
|
| 37 |
NCT02318602 |
Completed
Has Results |
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder |
|
- Drug: Cannabidiol Oral Solution
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Adverse Events
- Percentage of Participants With Serious Adverse Events
- Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Values
- (and 5 more...)
|
52 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02318602 |
INS011-14-030 |
|
January 8, 2016 |
June 22, 2017 |
June 22, 2017 |
December 17, 2014 |
July 25, 2018 |
July 25, 2018 |
- University of California San Francisco Medical Center
San Francisco, California, United States - Miami Children's Hospital
Miami, Florida, United States - Child Neurology Center - NW F
Pensacola, Florida, United States - (and 8 more...)
|
|
| 38 |
NCT02783092 |
Recruiting |
A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Antonio Waldo Zuardi
- Prati Donaduzzi & Cia Ltda
- University of Sao Paulo
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of epileptic seizures
|
126 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02783092 |
CBD-PRATI-USP_01 |
|
November 9, 2018 |
August 2020 |
December 2020 |
May 26, 2016 |
November 27, 2018 |
|
- Unidade de Pesquisa Clínica HCRP-USP
Ribeirao Preto, Sao Paulo, Brazil
|
|
| 39 |
NCT02392780 |
Unknown † |
Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease |
- Acute-graft-versus-host Disease
|
- Drug: Cannabidiol
- Drug: Methylprednisolone
- Drug: Calcineurin inhibitor
|
Interventional
|
Phase 2 |
- moshe yeshurun
- Rabin Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with complete remission of acute GVHD
- Proportion of patients with partial remission of acute GVHD
- Proportion of patients with chronic GVHD
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02392780 |
0009-15-RMC |
|
April 2015 |
April 2018 |
|
March 19, 2015 |
March 19, 2015 |
|
- Davidof Cancer Center, Beilinson hospital, Rabin medical center
Petach Tikva, Israel
|
|
| 40 |
NCT01844687 |
Completed
Has Results |
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana |
|
|
Interventional
|
Phase 2 |
- Steve Sparenborg
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Mood Scale - Subscale 'Feeling High'
|
50 |
All |
18 Years to 50 Years (Adult) |
NCT01844687 |
Study Number CBD-001 |
|
May 2013 |
October 2014 |
October 2014 |
May 1, 2013 |
April 25, 2017 |
April 25, 2017 |
- University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct.
Lexington, Kentucky, United States - Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120
New York, New York, United States - Center for Drug and Alcohol Programs, Room 459 North, 67 President St.
Charleston, South Carolina, United States
|
|
| 41 |
NCT03215940 |
Recruiting |
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC) |
|
- Drug: Delta-9-Tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebos
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Brain Changes
- Improvement in pain relief
|
75 |
All |
18 Years to 50 Years (Adult) |
NCT03215940 |
IRB_00103451 |
|
February 1, 2018 |
October 2019 |
December 2019 |
July 12, 2017 |
January 9, 2019 |
|
- University Of Utah
Salt Lake City, Utah, United States
|
|
| 42 |
NCT02088060 |
Active, not recruiting |
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients |
|
- Drug: Cannabidiol
- Drug: Olanzapine
- Drug: Placebo Cannabidiol
- Drug: Placebo Olanzapine
|
Interventional
|
Phase 2 |
- Central Institute of Mental Health, Mannheim
- Martin-Luther-Universität Halle-Wittenberg
- Heidelberg University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Positive and Negative Syndrome Scale (PANSS) total score
- Changes in the PANSS subscores and clusters
- Changes in the Clinical Global Impression score
- (and 10 more...)
|
150 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02088060 |
CBD-FEP
2012-004335-23 |
|
March 2014 |
August 2021 |
December 2021 |
March 14, 2014 |
March 8, 2018 |
|
- Psychiatric Centre Glostrup
Glostrup, Denmark - Department of General Psychiatry, Heidelberg University
Heidelberg, BW, Germany - Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, BW, Germany - (and 3 more...)
|
|
| 43 |
NCT02461706 |
No longer available |
Treatment of Drug Resistant Epilepsy |
|
- Drug: cannabidiol
- Other: Blood Test
|
Expanded Access
|
|
- University of Florida
- James and Esther King Biomedical Research Program
|
Other |
|
|
|
All |
2 Years to 16 Years (Child) |
NCT02461706 |
IRB201401013
FLGV |
Cannabidiol |
|
|
|
June 3, 2015 |
January 21, 2019 |
|
- University of Flordia CRC
Gainesville, Florida, United States - Nicklaus Children's Hospital, Miami Children's Health System
Miami, Florida, United States
|
|
| 44 |
NCT02953548 |
Active, not recruiting |
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experienced a treatment-emergent adverse event.
- Number of participants with a potentially clinically significant change in clinical laboratory tests.
- Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
- (and 4 more...)
|
10 |
All |
1 Month to 24 Months (Child) |
NCT02953548 |
GWEP15100 Pilot Phase
2015-004904-50 |
|
March 16, 2017 |
October 2018 |
October 2018 |
November 2, 2016 |
July 17, 2018 |
|
- Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States - Nationwide Children's Hospital
Columbus, Ohio, United States - Le Bonheur Children's Hospital
Memphis, Tennessee, United States - (and 3 more...)
|
|
| 45 |
NCT02224703 |
Unknown † |
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome |
|
- Drug: GWP42003-P
- Drug: Placebo Control
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage change from baseline in convulsive seizure frequency during the treatment period.
- Number of subjects considered treatment responders, defined as those with a ≥25%, ≥50% or ≥75% reduction in convulsive seizures from baseline.
- Number of subjects who are convulsive seizure free.
- (and 5 more...)
|
150 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02224703 |
GWEP1424
2014-002939-34 |
|
March 2015 |
May 2017 |
June 2017 |
August 25, 2014 |
October 12, 2016 |
|
- Sutter Neuroscience Institute
Sacramento, California, United States - Miami Children's Hospital
Miami, Florida, United States - McFarland Clinic
Ames, Iowa, United States - (and 7 more...)
|
|
| 46 |
NCT02051387 |
Completed |
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study |
|
- Drug: Cannabidiol CR
- Drug: Cannabidiol
- Drug: Amisulpride
- (and 4 more...)
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
- University of Cologne
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Plasma levels of cannabidiol
- Area Under Curve (AUC)
- serum antipsychotic concentration
|
74 |
All |
18 Years to 45 Years (Adult) |
NCT02051387 |
CBD-IS
2008-008245-38 |
CBD-IS |
January 2013 |
August 2017 |
August 2017 |
January 31, 2014 |
March 8, 2018 |
|
- Central Institute of Mental Health
Mannheim, BW, Germany - Dept. of Pharmacology, University of Cologne
Cologne, NRW, Germany
|
|
| 47 |
NCT02954887 |
Active, not recruiting |
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7) |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experienced a treatment-emergent adverse event.
- Number of participants with a potentially clinically significant change in clinical laboratory tests.
- Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
- (and 11 more...)
|
202 |
All |
1 Month to 24 Months (Child) |
NCT02954887 |
GWEP15100 Open-label Extension
2015-004904-50 |
|
May 9, 2017 |
December 2018 |
December 2018 |
November 4, 2016 |
July 16, 2018 |
|
- Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States - Nationwide Children's Hospital
Columbus, Ohio, United States - Le Bonheur Children's Hospital
Memphis, Tennessee, United States - (and 3 more...)
|
|
| 48 |
NCT03582137 |
Recruiting |
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease |
|
- Drug: Cannabidiol
- Other: Placebo
|
Interventional
|
Phase 2 |
- University of Colorado, Denver
- Colorado Department of Public Health and Environment
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Movement Disorders Society-Unified Parkinson's disease rating scale (MDS-UPDRS) Part III (motor examination) scores
- Change in Frequency of study-related adverse events
- Change in Liver function monitoring --Liver function test
- (and 54 more...)
|
75 |
All |
40 Years to 85 Years (Adult, Older Adult) |
NCT03582137 |
17-2318 |
|
September 17, 2018 |
December 2019 |
June 2020 |
July 10, 2018 |
January 21, 2019 |
|
- University of Colorado hospital
Aurora, Colorado, United States
|
|
| 49 |
NCT02044809 |
Completed |
Cannabidiol: a Novel Intervention for Cannabis Use Problems? |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University College, London
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine (THC-COOH:creatinine)
- Number of days abstinent from cannabis
- Diagnostic and Statistical Manual- 5 (DSM-5) criteria for moderate cannabis dependence
- (and 2 more...)
|
82 |
All |
16 Years to 60 Years (Child, Adult) |
NCT02044809 |
12/0278 |
|
March 2014 |
February 9, 2017 |
June 5, 2017 |
January 24, 2014 |
October 24, 2018 |
|
- Clinical Psychopharmacology Unit
London, United Kingdom
|
|
| 50 |
NCT02478424 |
Unknown † |
Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease |
|
- Drug: Cannabidiol
- Drug: cyclosporine
- Drug: Methotrexate
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of grade 2-4 and grade 3-4 acute GVHD by day 100
- grade 3-4 adverse effects attributed to CBD consumption
- Incidence of overall chronic GVHD and moderate to severe chronic GVHD by 12 months
- (and 6 more...)
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT02478424 |
RMC-0208-14 |
|
July 2015 |
December 2016 |
June 2017 |
June 23, 2015 |
June 23, 2015 |
|
|
|
| 51 |
NCT02910297 |
Withdrawn |
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy |
- Dravet Syndrome
- Lennox Gastaut Syndrome
|
|
Observational
|
|
- Gillette Children's Specialty Healthcare
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Reduction in seizures
- Cannabidiol concentration
|
0 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02910297 |
CBD-PK-1 |
|
September 2016 |
December 31, 2017 |
December 31, 2017 |
September 22, 2016 |
February 21, 2018 |
|
|
|
| 52 |
NCT00309413 |
Completed |
A Clinical Trial on the Antipsychotic Properties of Cannabidiol |
- Schizophrenia
- Psychotic Disorders
|
- Drug: Placebo/Cannabidiol
- Drug: Cannabidiol/Placebo
|
Interventional
|
Phase 2 |
- University of Cologne
- Stanley Medical Research Institute
- Coordinating Centre for Clinical Trials Cologne
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- BPRS
- PANSS, EPS, Prolactin, ECG etc.
|
29 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00309413 |
CBD-PT 04-153 |
|
March 2006 |
March 2008 |
July 2008 |
March 31, 2006 |
July 25, 2008 |
|
- University of Cologne, Dept. of Psychiatry and Psychotherapy
Cologne, NRW, Germany
|
|
| 53 |
NCT02083874 |
Unknown † |
Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study |
|
|
Interventional
|
Phase 2 |
- The University of New South Wales
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Severity of cannabis withdrawal
- Safety of CBD for cannabis withdrawal
- Treatment retention
|
5 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02083874 |
NCPIC2014001 |
|
March 2014 |
September 2014 |
December 2014 |
March 11, 2014 |
March 11, 2014 |
|
|
|
| 54 |
NCT02224573 |
Enrolling by invitation |
GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes |
- Epilepsy
- Dravet Syndrome
- Lennox-Gastaut Syndrome
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The incidence of adverse events and other assessments as measure of subject safety.
- Mean change in quality of life, relative to the pre-randomization baseline of the Core Study, if assessed during the Core Study.
- Changes in the Caregiver Global Impression of Change (CGIC) or Subject Global Impression of Change score, relative to the pre-randomization baseline of the Core Study, if assessed during the Core Study.
- (and 8 more...)
|
680 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT02224573 |
GWEP1415
2014-001834-27 |
|
June 2015 |
June 2019 |
June 2019 |
August 25, 2014 |
October 24, 2017 |
|
|
|
| 55 |
NCT02926859 |
Recruiting |
Enhancing Recovery in Early Schizophrenia |
|
- Drug: Cannabidiol as add-on
- Drug: Placebo as add-on
|
Interventional
|
Phase 2 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- All-cause discontinuation
- Improvement in Psychopathology assessed by PANSS
- Improvement in Psychopathology assessed by CGI
- (and 16 more...)
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02926859 |
CBD-ESPRIT |
|
April 8, 2017 |
March 2019 |
March 2019 |
October 6, 2016 |
January 8, 2019 |
|
- Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, BW, Germany - Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich
Munich, BY, Germany - Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte
Berlin, B, Germany - (and 2 more...)
|
|
| 56 |
NCT02504151 |
Active, not recruiting |
Cannabidiol Treatment in Patients With Early Psychosis |
- Schizophrenia
- Schizoaffective Disorder
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Positive and Negative Sydrome Scale
- Clinical Global Impression of Severity scale
- Patient Assessment of Own Functioning Inventory
- Quality of Life Scale
|
72 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02504151 |
1412015000 |
CBD |
August 2015 |
August 2019 |
December 2019 |
July 21, 2015 |
October 15, 2018 |
|
- Connecticut Mental Health Center
New Haven, Connecticut, United States - VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 57 |
NCT02224690 |
Completed
Has Results |
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults |
- Epilepsy
- Lennox-Gastaut Syndrome
|
- Drug: GWP42003-P 20 mg/kg/day Dose
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
- Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period
- Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
- Subject/Caregiver Global Impression Of Change Assessment (S/CGIC)
|
171 |
All |
2 Years to 55 Years (Child, Adult) |
NCT02224690 |
GWEP1423
2014-002941-23 |
GWPCARE4 |
April 28, 2015 |
March 18, 2016 |
March 18, 2016 |
August 25, 2014 |
July 27, 2018 |
July 27, 2018 |
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- (and 21 more...)
|
|
| 58 |
NCT02447198 |
Completed |
Cannabidiol (CBD) and Pediatric Epilepsy |
|
|
Observational
|
|
- University of Colorado, Denver
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Describe the plasma pharmacokinetics of Cannabidiol (CBD), other antiepileptic drugs, Tetrahydrocannibinol (THC), and their respective metabolites in pediatric patients with epilepsy.
- Demographic Data
- Medication History
- (and 2 more...)
|
42 |
All |
31 Days to 17 Years (Child) |
NCT02447198 |
15-0216
UL1TR001082 |
|
November 2, 2015 |
September 11, 2018 |
September 11, 2018 |
May 18, 2015 |
October 30, 2018 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
|
| 59 |
NCT03024827 |
Recruiting |
Cannabidiol in Children With Refractory Epileptic Encephalopathy |
|
|
Interventional
|
Phase 1 |
- University of Saskatchewan
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Heart Rate
- Blood Pressure
- Weight
- (and 19 more...)
|
28 |
All |
1 Year to 10 Years (Child) |
NCT03024827 |
CARE-E-01 |
CARE-E |
April 26, 2017 |
July 2019 |
December 2019 |
January 19, 2017 |
October 15, 2018 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - University of Manitoba
Winnipeg, Manitoba, Canada - Universite de Montreal
Montreal, Quebec, Canada - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
|
|
| 60 |
NCT02564952 |
Completed
Has Results |
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol |
|
- Drug: GWP42003-P
- Drug: Clobazam
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number Of Participants Who Experienced Severe OLE-Emergent AEs
|
18 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02564952 |
GWEP1428 Open-Label Extension
2014-002942-33 |
|
March 11, 2016 |
June 7, 2017 |
June 7, 2017 |
October 1, 2015 |
September 11, 2018 |
September 11, 2018 |
- Barcelona, Spain
- Barcelona, Spain
- Birmingham, United Kingdom
- (and 3 more...)
|
|
| 61 |
NCT01893424 |
Completed |
Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol) |
|
- Drug: Sativex buccal spray
- Drug: CBD-THC-Piperine-PNL capsule
|
Interventional
|
Phase 1 |
- Hadassah Medical Organization
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Pharmacokinetic parameters of THC and CBD
- exposure to the metabolites of the study drugs
|
12 |
Male |
18 Years to 45 Years (Adult) |
NCT01893424 |
0658-12-HMO-CTIL |
|
August 2013 |
January 2014 |
January 2015 |
July 9, 2013 |
March 24, 2016 |
|
- Hadassah medical organization
Jerusalem, Israel
|
|
| 62 |
NCT03295903 |
Not yet recruiting |
Cannabinoid Supplementation on Vascular and Cognitive Function |
|
- Dietary Supplement: Cannabidiol supplement
|
Interventional
|
Early Phase 1 |
- University of British Columbia
- Lexaria Bioscoence Corp
- Mitacs
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Circulating cannabidiol and nitric oxide markers
- Vascular function
- Height
- (and 11 more...)
|
24 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03295903 |
H17-01957 |
|
October 2017 |
July 2019 |
August 2019 |
September 28, 2017 |
September 28, 2017 |
|
- University of British Columbia
Kelowna, Ontario, Canada
|
|
| 63 |
NCT02544763 |
Active, not recruiting |
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
- Tuberous Sclerosis Complex
- Seizures
|
- Drug: GWP42003-P
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in seizure frequency
- Number of treatment responders
- Number of participants with worsening, no change, or improvements in seizure frequency
- (and 18 more...)
|
210 |
All |
1 Year to 65 Years (Child, Adult, Older Adult) |
NCT02544763 |
GWEP1521 Blinded Phase
2015-002154-12 |
|
April 2016 |
February 2019 |
February 2019 |
September 9, 2015 |
September 26, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 64 |
NCT00588731 |
Completed
Has Results |
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia |
- Schizophrenia
- Schizoaffective Disorder
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Yale University
- Stanley Medical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Verbal Short Term Memory
- Overall Cognition as Measured on the MATRICS Battery
|
41 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00588731 |
0710003164
07TGS-1082 |
|
February 2009 |
December 2013 |
December 2013 |
January 9, 2008 |
June 8, 2017 |
June 8, 2017 |
- Yale University
New Haven, Connecticut, United States
|
|
| 65 |
NCT00628290 |
Completed |
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis |
|
- Drug: Cannabidiol
- Drug: Amisulpride
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in BPRS total value.
- Change in PANSS scores.
- EPS
- (and 2 more...)
|
42 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00628290 |
CBD-CT1
SMRI Grant ID: 00-093 |
CBD-CT1 |
October 2002 |
November 2004 |
March 2008 |
March 5, 2008 |
March 18, 2008 |
|
- University of Cologne, Dept. of Psychiatry and Psychotherapy
Cologne, NRW, Germany
|
|
| 66 |
NCT02544750 |
Enrolling by invitation |
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) |
- Tuberous Sclerosis Complex
- Seizures
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events
- Change in seizure frequency
- Number of treatment responders
- (and 18 more...)
|
210 |
All |
1 Year to 65 Years (Child, Adult, Older Adult) |
NCT02544750 |
GWEP1521 Open-Label Extension
2015-002154-12 |
|
August 2016 |
February 2022 |
February 2022 |
September 9, 2015 |
October 1, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 67 |
NCT02291536 |
Completed |
Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD) |
|
- Drug: tetrahydrocannabinol
- Drug: cannabidiol
- Other: placebo
|
Interventional
|
Not Applicable |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Correctly identified emotional pictures during the attentional blink period
- Reaction time to correctly identified emotional pictures during the attentional blink period
|
20 |
Male |
18 Years to 65 Years (Adult, Older Adult) |
NCT02291536 |
AB_THC_CBD |
AB_THC_CBD |
February 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
January 16, 2015 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
| 68 |
NCT02777502 |
Recruiting |
Effects of Cannabidiol on Marijuana-seeking in Humans |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Marijuana Craving Visual Analog Scale (VAS) (Self-report measure)
- Marijuana Craving Questionnaire (Self-report measure)
- Marijuana Rating Form (Self-report measure)
- (and 10 more...)
|
25 |
All |
21 Years to 45 Years (Adult) |
NCT02777502 |
CBD-1 |
|
January 1, 2016 |
December 2018 |
December 2018 |
May 19, 2016 |
October 4, 2018 |
|
- Tolan Park Medical Building
Detroit, Michigan, United States
|
|
| 69 |
NCT02565108 |
Completed
Has Results |
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol |
|
- Drug: GWP42003-P 20 mg/kg/Day Dose
- Drug: Placebo
- Drug: Clobazam
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
- PK: Time To The Maximum Plasma Concentration (Tmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
- PK: Area Under The Plasma Concentration‑Time Curve Over A Dosing Interval, Where Tau Is The Dosing Interval (AUCtau) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33
- (and 3 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02565108 |
GWEP1428 Blinded Phase
2014-002942-33 |
|
January 20, 2016 |
July 21, 2016 |
July 21, 2016 |
October 1, 2015 |
August 23, 2018 |
August 23, 2018 |
- Barcelona, Spain
- Barcelona, Spain
- Birmingham, United Kingdom
- (and 3 more...)
|
|
| 70 |
NCT01180374 |
Active, not recruiting |
The Effects of Cannabidiol and ∆-9-THC in Humans |
|
- Drug: Cannabidiol
- Drug: Delta-9-THC
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
|
75 |
All |
18 Years to 55 Years (Adult) |
NCT01180374 |
1001006240 |
|
June 2010 |
July 2019 |
July 2019 |
August 12, 2010 |
June 6, 2018 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
|
| 71 |
NCT02987114 |
Completed |
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy |
|
|
Interventional
|
Phase 2 |
- PhytoTech Therapeutics, Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of study treatment related adverse events (AEs)
- Percent change in mean countable monthly seizure frequency
- Incidence of all adverse events (AEs)
- (and 2 more...)
|
16 |
All |
2 Years to 15 Years (Child) |
NCT02987114 |
CS-100 |
|
February 13, 2017 |
June 28, 2018 |
June 28, 2018 |
December 8, 2016 |
September 6, 2018 |
|
- Pediatric Epilepsy department- Souraskey Medical center
Tel Aviv, Israel
|
|
| 72 |
NCT02091375 |
Completed
Has Results |
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) |
|
- Drug: GWP42003-P 20 mg/kg/day Dose
- Drug: Placebo control
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period
- Number Of Participants With A ≥50% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
- Number of Participants With A ≥25%, ≥75% Or 100% Reduction From Baseline In Convulsive Seizure Frequency During The Treatment Period
- (and 9 more...)
|
120 |
All |
2 Years to 18 Years (Child, Adult) |
NCT02091375 |
GWEP1332 Part B
2014-002941-23 |
|
March 30, 2015 |
November 26, 2015 |
November 26, 2015 |
March 19, 2014 |
August 27, 2018 |
July 20, 2018 |
- Miami, Florida, United States
- Orlando, Florida, United States
- Atlanta, Georgia, United States
- (and 19 more...)
|
|
| 73 |
NCT03840512 |
Recruiting
New |
An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD) |
|
|
Interventional
|
Phase 2 |
- Kalytera Therapeutics Israel, Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Adverse Events (AEs) and serious adverse events (SAEs) Reporting
- Cumulative incidence of aGVHD at day 100 post-transplant
- Pharmacokinetic parameters of Cannabidiol (CBD) - Cmax
- (and 7 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03840512 |
KAL05 |
|
August 1, 2018 |
October 15, 2019 |
November 15, 2019 |
February 15, 2019 |
February 15, 2019 |
|
- St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
Sydney, Australia - Rambam Health Care - Bone Marrow Transplantation Unit
Haifa, Israel - Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center
Jerusalem, Israel - (and 2 more...)
|
|
| 74 |
NCT02695537 |
Active, not recruiting |
Safety, and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy |
|
|
Interventional
|
Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate severe adverse events (increase in seizure frequency by more than 25% or any hospitalization related to increase in seizure frequency)
- Evaluate change in resting blood pressure or heart rate by 25%
- Evaluate any change in, CBC, CMP, Liver function tests (LFTSs ), Urinary Analysis or Antiepileptic drug (AED) levels considered by managing neurologists as clinically significant.
- (and 2 more...)
|
100 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02695537 |
IND# 124160 |
|
April 2015 |
February 2020 |
February 2020 |
March 1, 2016 |
November 30, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 75 |
NCT02397863 |
Available |
Epidiolex and Drug Resistant Epilepsy in Children |
|
- Drug: Cannabidiol (Epidiolex)
|
Expanded Access
|
|
- Augusta University
- State of Georgia
|
Other |
|
|
|
All |
1 Year to 18 Years (Child, Adult) |
NCT02397863 |
CBD02 |
CBD |
December 2014 |
December 2019 |
January 2020 |
March 25, 2015 |
April 24, 2015 |
|
- Georgia Regents University
Augusta, Georgia, United States
|
|
| 76 |
NCT02607891 |
Recruiting |
A Study to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy |
|
- Drug: GWP42003-P
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD).
- Time to the maximum plasma concentration (Tmax) of STP, VPA and CBD.
- Area under the curve (AUC) from zero to final time of positive detection (0-t) of STP, VPA and CBD.
- (and 15 more...)
|
40 |
All |
16 Years to 55 Years (Child, Adult) |
NCT02607891 |
GWEP1447 Blinded Phase
2015-002939-18 |
|
October 2016 |
August 2018 |
August 2018 |
November 18, 2015 |
November 1, 2017 |
|
- Elancourt, France
- Paris, France
- Rennes, France
- (and 7 more...)
|
|
| 77 |
NCT03003260 |
Unknown † |
The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel Syndrome |
|
- Other: CBD chewing gum
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change of pain scores on the Visual analoge scale (VAS) between baseline and 3, 5 and 8 weeks of treatment
- Change of IBS-QOL baseline vs 3, 5 and 8 weeks of treatment
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03003260 |
NL58588.081.16 |
|
December 2016 |
April 2017 |
June 2017 |
December 26, 2016 |
December 26, 2016 |
|
- Wageningen University
Wageningen, Gelderland, Netherlands
|
|
| 78 |
NCT03825965 |
Not yet recruiting
New |
Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT |
|
- Drug: Cannabidiol (CBD)
- Drug: Placebo oral capsule
|
Interventional
|
Phase 3 |
- McMaster University
- Michael G. DeGroote Centre for Medicinal Cannabis Research
- Michael G. DeGroote National Pain Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Persistent post-surgical pain (PPSP)
- Opioid use
- Peri-operative pain intensity
- (and 7 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03825965 |
Cannabis TKA Pilot Trial |
|
April 2019 |
April 2021 |
April 2021 |
February 1, 2019 |
February 1, 2019 |
|
- St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada - Hamilton Health Sciences - Juravinski Hospital
Hamilton, Ontario, Canada
|
|
| 79 |
NCT02291562 |
Completed |
Effects of THC and CBD on Human Episodic Memory Function |
|
- Drug: Tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: placebo
|
Interventional
|
Not Applicable |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Changes in BOLD (blood oxygen level dependent) responses
- Changes in behavioral measures
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT02291562 |
LOGIN_EpMem |
|
July 2014 |
December 2014 |
December 2014 |
November 14, 2014 |
January 16, 2015 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
| 80 |
NCT02607904 |
Enrolling by invitation |
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who experienced an adverse event.
- Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).
- Number of participants with a clinically significant change in serum biochemistry.
- (and 7 more...)
|
40 |
All |
16 Years to 55 Years (Child, Adult) |
NCT02607904 |
GWEP1447 Open-label Extension
2015-002939-18 |
|
November 2016 |
August 2019 |
August 2019 |
November 18, 2015 |
November 1, 2017 |
|
|
|
| 81 |
NCT02751359 |
Active, not recruiting |
Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers |
|
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- New York State Psychiatric Institute
- INSYS Therapeutics Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Analgesia: Pain tolerance and threshold as measured by the Cold Pressor Test
- Subjective drug effects related to abuse liability as measured by visual analog scales
|
18 |
All |
21 Years to 50 Years (Adult) |
NCT02751359 |
7009 |
|
June 2016 |
December 2018 |
December 2018 |
April 26, 2016 |
April 9, 2018 |
|
- Cooper
New York, New York, United States
|
|
| 82 |
NCT02700412 |
Active, not recruiting |
University of Alabama at Birmingham (UAB) Adult CBD Program |
|
|
Interventional
|
Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate severe adverse events (increase in seizure frequency by more than 100% or any hospitalization related to increase in seizure frequency)
- Evaluate any change in resting blood pressure or heart rate by 25%
- Evaluate any change in, CBC, CMP, Liver function tests (LFTSs), Urinary Analysis or Antiepileptic drug (AED) levels considered by managing neurologists as clinically significant.
- (and 2 more...)
|
100 |
All |
15 Years to 99 Years (Child, Adult, Older Adult) |
NCT02700412 |
IND# 124138 |
|
April 2015 |
April 2019 |
April 2019 |
March 7, 2016 |
June 29, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 83 |
NCT02224560 |
Completed
Has Results |
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults |
- Epilepsy
- Lennox Gastaut Syndrome
|
- Drug: GWP42003-P
- Drug: Placebo control
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
- Number Of Participants With A ≥50% Reduction From Baseline In Drop Seizure Frequency During The Treatment Period
- Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
- Subject/Caregiver Global Impression Of Change (S/CGIC) Assessment
|
225 |
All |
2 Years to 55 Years (Child, Adult) |
NCT02224560 |
GWEP1414
2014-002940-42 |
GWPCARE3 |
June 8, 2015 |
May 19, 2016 |
May 19, 2016 |
August 25, 2014 |
July 27, 2018 |
July 27, 2018 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Los Angeles, California, United States
- (and 26 more...)
|
|
| 84 |
NCT03607643 |
Not yet recruiting |
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
- Cancer of Pancreas
- Cancer of Liver
- Cancer of Rectum
- (and 4 more...)
|
- Drug: Cannabidiol
- Drug: Bortezomib
- Drug: Leucovorin
- (and 6 more...)
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Response rate
- Time to progression (TTP) in patients using lab results and radiographic data.
- Progression-free survival (PFS) in patients using lab results and radiographic data.
- (and 2 more...)
|
160 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03607643 |
Olympian |
|
January 15, 2019 |
June 30, 2020 |
December 15, 2020 |
July 31, 2018 |
July 31, 2018 |
|
- Southwest Cancer Center
Orlando, Florida, United States
|
|
| 85 |
NCT02255292 |
Unknown † |
A Study: Pure CBD as Single-agent for Solid Tumor. |
|
|
Interventional
|
Phase 2 |
- Hadassah Medical Organization
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate according to RECIST 1.1
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02255292 |
CBD- HMO-CTIL |
|
November 2014 |
July 2015 |
July 2015 |
October 2, 2014 |
October 2, 2014 |
|
|
|
| 86 |
NCT02539823 |
Completed |
Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans |
|
- Drug: CBD 400 mg
- Drug: CBD 800 mg
- Drug: Control (placebo)
|
Interventional
|
Phase 2 |
- Hurd,Yasmin, Ph.D.
- GW Research Ltd
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Cue-Induced In-Clinic Craving (from baseline to post-cue (30 minutes), and from test visit 1 through test visit 4 (1 week)) - via the Visual Analog Scale for Craving (VASC)
- Changes in Out-of-Clinic Craving (from pre-dose to approximately 4-6 hours post-dose; and from test visit 1 to test visit 4 or 1 week) - via the Heroin Craving Questionnaire (HCQ)
- Vital Signs
|
45 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT02539823 |
MSBI HSM# 087-14 |
|
September 2015 |
May 24, 2017 |
May 24, 2017 |
September 3, 2015 |
February 21, 2018 |
|
- Mount Sinai Beth Israel
New York, New York, United States
|
|
| 87 |
NCT02492074 |
Not yet recruiting |
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study |
- Healthy Volunteers
- Modeling Psychosis
|
- Drug: Delta-9-tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Positive and Negative Syndrome Scale (total score, PANSS T) from baseline to post drug intake of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and D2-receptor availability
- Change in PANSS subscores and clusters (baseline to post drug intake)
- Change in Digit Symbol Coding
- (and 11 more...)
|
60 |
Male |
18 Years to 45 Years (Adult) |
NCT02492074 |
GEI-TCP I |
|
April 2019 |
April 2020 |
May 2020 |
July 8, 2015 |
March 15, 2018 |
|
- Central Institute of Mental Health
Mannheim, BW, Germany
|
|
| 88 |
NCT02932605 |
Recruiting |
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia |
|
- Drug: Placebo
- Drug: Cannabidiol
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- the concentration of prefrontal metabolites as measured with 1H-MRS
- Tolerability associated with CBD treatment
- Psychotic symptoms
- (and 12 more...)
|
36 |
All |
16 Years to 40 Years (Child, Adult) |
NCT02932605 |
ABR58805
2016-003529-41 |
CANGLIA |
November 3, 2017 |
January 2020 |
January 2020 |
October 13, 2016 |
June 11, 2018 |
|
- University Medical Center Utrecht
Utrecht, Netherlands
|
|
| 89 |
NCT03398083 |
Completed |
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam |
|
- Drug: THC
- Drug: Alprazolam
- Drug: Placebo oral capsule
- Drug: CBD
|
Interventional
|
Phase 1 |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Diagnostic
|
- Visual Analog Scale
- Incidence of Increased Vital Signs
- Incidence of Increased ECG Reading
- Incidence of Clinically Significant Laboratory Values
|
42 |
All |
18 Years to 55 Years (Adult) |
NCT03398083 |
NIDA-CBD-Phase1-001 |
|
December 4, 2017 |
May 30, 2018 |
May 30, 2018 |
January 12, 2018 |
June 14, 2018 |
|
- Debra Kelsh, MD
Overland Park, Kansas, United States
|
|
| 90 |
NCT02091206 |
Completed
Has Results |
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) |
|
- Drug: GWP42003-P 5 mg/kg/day Dose
- Drug: Placebo control
- Drug: GWP42003-P 10 mg/kg/day Dose
- Drug: GWP42003-P 20 mg/kg/day Dose
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs)
- Area Under The Concentration-Time Curve Calculated To The Last Observable Concentration At Time T (AUC0-t) For CBD And Its Metabolites At Days 1 And 22
- Mean Percentage Change From Baseline To End Of Treatment In Plasma Clobazam (CLB) And N-Desmethylclobazam (N-CLB) Concentrations
|
34 |
All |
4 Years to 10 Years (Child) |
NCT02091206 |
GWEP1332 Part A
2014-002941-23 |
|
October 22, 2014 |
March 9, 2015 |
March 9, 2015 |
March 19, 2014 |
August 24, 2018 |
July 19, 2018 |
- Miami, Florida, United States
- Atlanta, Georgia, United States
- Chicago, Illinois, United States
- (and 8 more...)
|
|
| 91 |
NCT03802799 |
Recruiting |
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS |
|
- Drug: ZYN002 - CBD Transdermal Gel
|
Interventional
|
Phase 2
Phase 3 |
- Zynerba Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events (safety and tolerability)
- Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1
- Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 2
- Clinical Global Impression- Improvement (CGI-I)
|
300 |
All |
3 Years to 18 Years (Child, Adult) |
NCT03802799 |
ZYN2-CL-017 |
|
November 9, 2018 |
September 30, 2019 |
September 30, 2020 |
January 14, 2019 |
January 14, 2019 |
|
- Southwest Autism Research and Resource Center
Phoenix, Arizona, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - UC Davis Health System, MIND Institute
Sacramento, California, United States - (and 18 more...)
|
|
| 92 |
NCT03614663 |
Recruiting |
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) |
|
- Drug: ZYN002 - CBD Transdermal Gel
- Other: Placebo Transdermal Gel
|
Interventional
|
Phase 2
Phase 3 |
- Zynerba Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1
- Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 2
- Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 3
- Clinical Global Impressions- Improvement (CGI-I)
|
204 |
All |
3 Years to 17 Years (Child) |
NCT03614663 |
ZYN2-CL-016 |
CONNECT-FX |
June 12, 2018 |
July 23, 2019 |
October 29, 2019 |
August 3, 2018 |
January 17, 2019 |
|
- Southwest Autism Research and Resource Center
Phoenix, Arizona, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - UC Davis Health System, MIND Institute
Sacramento, California, United States - (and 18 more...)
|
|
| 93 |
NCT03693833 |
Recruiting |
CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis. |
- Psoriatic Arthritis
- Hand Osteoarthritis
|
- Drug: Cannabidiol
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 2 |
- Aalborg Universitetshospital
- Aalborg University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- VAS pain during the last 24 hours
|
180 |
All |
18 Years and older (Adult, Older Adult) |
NCT03693833 |
NordCAN |
NordCAN |
October 20, 2018 |
October 1, 2019 |
December 31, 2019 |
October 3, 2018 |
January 24, 2019 |
|
- Department of Rheumatology Aalborg Universityhospital North
Aalborg, Denmark
|
|
| 94 |
NCT02983695 |
Active, not recruiting |
Cannabinoid Therapy for Pediatric Epilepsy |
|
|
Interventional
|
Phase 1 |
- The Hospital for Sick Children
- Tilray
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Establishment of tolerability of TIL-TC150 by measuring the number of participants with adverse events and / or abnormal laboratory values that are related to treatment
- Establishment of tolerability of TIL-TC150 by standardised side effects questionnaire -pediatric epilepsy side effects questionnaire (PESQ)
- The impact of therapy on quality of life using the Quality of Life in Childhood Epilepsy (QOLCE) questionnaire
- (and 2 more...)
|
20 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02983695 |
1000047417 |
|
February 2, 2017 |
August 24, 2018 |
October 31, 2019 |
December 6, 2016 |
February 5, 2019 |
|
- The Hospital for Sick Children
Toronto, Ontario, Canada
|
|
| 95 |
NCT01284634 |
Completed
Has Results |
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease |
|
- Drug: GWP42003 200 mg/day Dose
- Drug: GWP42003 400 mg/day Dose
- Drug: GWP42003 800 mg/day Dose
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent Change From Baseline To The End Of Treatment (EOT) In Mean Liver Triglyceride Levels
- Change From Baseline To The EOT In Mean Serum Total Cholesterol Levels
- Change From Baseline To The EOT In Mean Serum High Density Lipoprotein (HDL)-Cholesterol(C) Levels
- (and 3 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT01284634 |
GWMD09112
2009-017080-41 |
|
May 3, 2011 |
July 13, 2012 |
July 13, 2012 |
January 27, 2011 |
August 8, 2018 |
January 20, 2014 |
- London, United Kingdom
- Manchester, United Kingdom
- Manchester, United Kingdom
|
|
| 96 |
NCT03537950 |
Active, not recruiting |
Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder |
|
- Drug: PLC
- Drug: CBD
- Drug: CBDV
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Brain biochemistry response to pharmacological stimulation
- Measurement of low frequency brain activity using resting state fMRI
- Measurement of brain functional connectivity using resting state fMRI
|
38 |
Male |
18 Years to 50 Years (Adult) |
NCT03537950 |
HR15-162744 |
|
August 22, 2016 |
February 16, 2017 |
April 27, 2019 |
May 25, 2018 |
May 25, 2018 |
|
- King's College London
London, United Kingdom
|
|
| 97 |
NCT02487381 |
Completed |
Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids |
- Healthy
- Modeling Psychosis
|
- Drug: delta-9-tetrahydrocannabinol
- Drug: Cannabidiol
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in Positive and Negative Syndrome Scale total score (PANSS T) from baseline to post drug intake of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and neural synchrony.
- Change in Positive and Negative Syndrome Scale (PANSS) subscores and clusters (baseline to post drug intake)
- Change in neuropsychological parameters
- (and 5 more...)
|
60 |
Male |
18 Years to 45 Years (Adult) |
NCT02487381 |
GEI-TCP II |
|
April 2015 |
July 2015 |
August 2015 |
July 1, 2015 |
August 17, 2015 |
|
- Central Institute of Mental Health
Mannheim, BW, Germany
|
|
| 98 |
NCT03832816 |
Not yet recruiting
New |
Behavioral and Physiological Effects of THC and CBD |
- Behavioral and Physiological Effects of CBD and THC
|
- Drug: Placebo
- Drug: Vaporized THC alone
- Drug: Vaporized CBD alone
- Drug: Vaporized CBD with THC
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in blood cortisol levels
- Change in blood Adrenocorticotropic hormone (ACTH) levels
- Change in heart rate
- (and 5 more...)
|
120 |
All |
18 Years to 50 Years (Adult) |
NCT03832816 |
IRB00199386 |
|
May 2019 |
May 2021 |
May 2021 |
February 6, 2019 |
February 6, 2019 |
|
- Johns Hopkins Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States
|
|
| 99 |
NCT02815540 |
Unknown † |
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy |
- Lennox-Gastaut Syndrome
- Dravet Syndrome
|
- Procedure: 15-Lead ECG
- Drug: Cannabadiol
|
Interventional
|
Not Applicable |
- Gillette Children's Specialty Healthcare
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- ECG parameters
- Holter heart rate parameters
- Seizure frequency
- Dysautonomia signs and symptoms
|
25 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02815540 |
CBD-001 |
CBD1 |
June 2016 |
June 2017 |
December 2017 |
June 28, 2016 |
June 28, 2016 |
|
- Gillette Children's Specialty Healthcare
St.Paul, Minnesota, United States
|
|
| 100 |
NCT01887301 |
Completed |
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic analysis - Unbound maximum plasma concentration (Cmax(u)) of Sativex® in healthy patients and in patients with hepatic impairment
- Pharmacokinetic analysis - Unbound area under the concentration-time curve calculated to the last observable concentration at time t (AUC0-t(u)) of Sativex® in healthy patients and in patients with hepatic impairment
- Pharmacokinetic analysis - Unbound Area under the concentration-time curve from time zero to infinity (AUC0-inf(u)) of Sativex® in healthy patients and in patients with hepatic impairment
- (and 7 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT01887301 |
GWCP10114 |
|
July 2013 |
May 2014 |
May 2014 |
June 26, 2013 |
June 4, 2014 |
|
- Anaheim Clinical Trials, LLC
Anaheim, California, United States - Clinical Pharmacology of Miami, Inc.
Miami, Florida, United States
|
|
Create an RSS feed from your search for:
Download the search results for: